Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Waddell, Tom; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor O.; Azevedo, Sergio Jobim; Borchiellini, Delphine; McDermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Wu, Sterling; Burgents, Joseph; Molife, L. Rhoda; Powles, Thomas

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

Author:

Rini, Brian I.; Plimack, Elizabeth R.; Stus, Viktor; Gafanov, Rustem; Waddell, Tom; Nosov, Dmitry; Pouliot, Frederic; Alekseev, Boris; Soulieres, Denis; Melichar, Bohuslav; Vynnychenko, Ihor O.; Azevedo, Sergio Jobim; Borchiellini, Delphine; McDermott, Raymond S.; Bedke, Jens; Tamada, Satoshi; Wu, Sterling; Burgents, Joseph; Molife, L. Rhoda; Powles, Thomas

Tübinger Autor(en):

Bedke, Jens

Published in:

Journal of Clinical Oncology (2023), Bd. 41, H. 17_SUPPL, S. LBA4501

Verlagsangabe:

Philadelphia : Lippincott Williams & Wilkins

Language:

English

Full text:

http://dx.doi.org/10.1200/JCO.2023.41.17_suppl.LBA4501

ISSN:

0732-183X